Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study
- PMID: 32647027
- DOI: 10.1136/annrheumdis-2020-218243
Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study
Keywords: biological therapy; cytokines; immune system diseases; inflammation.
Conflict of interest statement
Competing interests: MDN has received personal fees from Bayer, Daiichi Sankyo, Sanofi, Pfizer, Leo Pharma and Aspen, outside of the submitted work. AA has received research support from Novartis, Olatec and Swedish Orphan Biovitrum, outside of the submitted work.
Comment in
-
Rational use of tocilizumab in COVID-19.Ann Rheum Dis. 2022 Nov;81(11):e213. doi: 10.1136/annrheumdis-2020-218519. Epub 2020 Jul 31. Ann Rheum Dis. 2022. PMID: 32737106 No abstract available.
-
Response to: 'Rational use of tocilizumab in COVID-19' by Jain and Sharma.Ann Rheum Dis. 2022 Nov;81(11):e215. doi: 10.1136/annrheumdis-2020-218626. Epub 2020 Jul 31. Ann Rheum Dis. 2022. PMID: 32737108 No abstract available.
-
Response to: 'Correspondence on 'Interleukin-6 blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study' by Potere et al' by Buckley.Ann Rheum Dis. 2022 Oct;81(10):e195. doi: 10.1136/annrheumdis-2020-218715. Epub 2020 Sep 1. Ann Rheum Dis. 2022. PMID: 32873552 No abstract available.
-
Correspondence on 'Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study' by Potere et al.Ann Rheum Dis. 2022 Oct;81(10):e194. doi: 10.1136/annrheumdis-2020-218693. Epub 2020 Sep 1. Ann Rheum Dis. 2022. PMID: 32873553 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials